Last updated: February 21, 2026
What are the core issues in this litigation?
This case involves patent infringement and contractual disputes. Adapt Pharma Operations Limited alleges that Perrigo UK Finco Limited Partnership infringed patents related to nasal spray delivery systems. The litigation centers on whether Perrigo’s products violate patent rights held by Adapt Pharma, and whether contractual obligations or licensing agreements were breached.
What is the procedural history of the case?
The complaint was filed in the District Court for the District of New Jersey in October 2018. Since then, the case has involved multiple procedural stages:
- Initial pleadings filed in late 2018.
- Discovery phase from 2019 to 2020, with document exchanges and depositions.
- Motions for summary judgment filed by Perrigo in May 2021.
- A Markman hearing to interpret patent claims in August 2021.
- Court’s preliminary rulings issued in early 2022, with a trial scheduled for Q3 2022.
- No final judgment reported as of mid-2023; the case remains pending.
What are the patent claims involved?
The patent portfolio includes U.S. Patent Nos. 9,265,538 and 9,468,603, which cover delivery mechanisms for nasal spray medications, including specific pump formulations and spray devices. Adapt Pharma asserts exclusive rights to these patents, claiming Perrigo’s nasal spray products infringe on these innovations.
| Patent Number |
Filing Date |
Expiry Date |
Key Claims |
| 9,265,538 |
June 16, 2014 |
June 16, 2034 |
Pump mechanism for nasal spray |
| 9,468,603 |
September 8, 2014 |
September 8, 2034 |
Delivery system with specific flow control |
Perrigo contends that its products do not infringe, asserting design around and non-infringement defenses.
How do the contractual issues fit into the case?
The dispute also involves a licensing agreement, allegedly granting Adapt Pharma rights to certain patent rights, or restrictions on Perrigo’s use of patented technology. Perrigo argues that the licensing agreement was breached or does not apply to the products in question. This adds a contractual layer to the patent infringement claims, complicating settlement prospects and potential damages calculations.
What are the key legal arguments?
Adapt Pharma:
- Patent infringement through unauthorized use of patented nasal spray design.
- Breach of licensing agreement if Perrigo’s products violate licensing terms.
Perrigo:
- Non-infringement based on design-around technology.
- Invalidity of patents due to prior art or obviousness.
- No breach of licensing agreement; products fall outside scope.
What are the potential outcomes?
- Infringement ruling favoring Adapt Pharma: Court could issue an injunction blocking Perrigo from selling infringing products, along with damages.
- Invalidity of patents: If Perrigo succeeds on patent invalidity, the case could be dismissed, voiding Adapt Pharma’s claims.
- Contractual ruling: If the licensing agreement is deemed breached or invalid, damages or license termination may result.
What are the strategic implications?
- For Adapt Pharma: A favorable ruling could cement patent rights and restrict Perrigo’s nasal spray market share.
- For Perrigo: Success on invalidity or non-infringement would weaken Adapt Pharma’s position, reduce damages, and preserve market access.
- Market impact: A patent ruling may influence subsequent product development and licensing strategies within the nasal spray segment.
How has the case been influenced by broader legal trends?
Patent litigation in the pharmaceutical sector increasingly involves:
- Challenges based on obviousness and prior art.
- Use of claim construction hearings to influence case trajectory.
- Cross-ownership and licensing negotiations impacting enforcement strategies.
Judicial tendencies to scrutinize patent scope could favor defendants if patents are narrowly interpreted or proven invalid.
What are the current procedural and policy considerations?
The case illustrates the importance of:
- Precise patent claim drafting.
- Clear licensing agreements.
- Early claim construction hearings to define scope.
The outcome might influence future litigation approaches and patent strategy in the pharmaceutical device space.
Key Takeaways
- The case centers on patent infringement regarding nasal spray delivery systems.
- Patent validity, non-infringement, and licensing terms are critical points.
- Strategic patent claim drafting and robust licensing agreements matter for enforcement.
- Court decisions could significantly impact nasal spray market dynamics.
- Ongoing procedural developments include summary judgment motions and a scheduled trial.
Frequently Asked Questions
1. What are the main patents involved in this litigation?
The patents are U.S. Patent Nos. 9,265,538 and 9,468,603, covering specific pump and delivery mechanisms for nasal sprays (adapted from [1]).
2. How does the case impact the nasal spray market?
A ruling favoring Adapt Pharma could restrict Perrigo’s sales of certain nasal spray products, influencing market share. An invalidation of patents might open market opportunities for competitors.
3. What defenses does Perrigo raise against patent infringement?
Perrigo argues non-infringement, design-around technology, and patent invalidity due to prior art or obviousness (based on available filings).
4. Can licensing agreements influence the case outcome?
Yes, if Perrigo’s products violate licensing terms, damages or contractual remedies could be pursued. Conversely, invalid or unenforceable licenses could weaken Adapt Pharma’s position.
5. How long might this case last?
Given procedural delays, trial dates, and potential appeals, the case might extend into 2024 or beyond.
References
[1] United States Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com/patent/US9265538B2
